← Eichor
Study identifier: NCT05398003 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M)

Condition: Pain, Intractable  ·  Sponsor: Nantes University Hospital

PhaseNA
Planned participants12
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

Number of centres planned : 1 (CHU Nantes) Design : Randomized, Prospective Planning of the study : * Total duration: 34 months * Recruitment period: 24 months. * Follow-up time per patients : 7-10 months Expected number of cases : 12 Treatment, procedure, combination of procedures under consideration : During the study, patients will be implanted with the WAVEWRITER ALPHA™ system with the objective of decreasing patient pain with a spinal cord stimulation mode. There will be a random draw on the order of the stimulation program: * the tonic stimulation "LF": In tonic mode, the electrical stimulation of the sensory fibers of the posterior cords of the spinal cord induces local paresthesias * burst stimulation (or "burst") * high frequency" stimulation (1000 Hz) "High frequency: HF". * combined tonic + burst stimulation * combined tonic + high frequency stimulation

This description comes directly from the study's public registry record.

Talk to the study team

Sylvie RAOUL  ·  02 40 16 50 80  ·  sylvie.raoul@chu-nantes.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de NantesNantes, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05398003